ArticleAntimicrobial agents and chemotherapy2020
Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
Anna E Grzegorzewicz, Joël Lelièvre, Jorge Esquivias, Bhanupriya Angala, Jiuyu Liu, Richard E Lee, Michael R McNeil, Mary Jackson
Open access · greenAbstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 4 institutions in 3 countries.
Anna E GrzegorzewiczMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Joël LelièvreDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Jorge EsquiviasDiseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Bhanupriya AngalaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Jiuyu LiuDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Richard E LeeDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Michael R McNeilMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA mary.jackson@colostate.edu.ORCID 0000-0002-9212-0258 Colorado State University · USGlaxoSmithKline (Spain) · ESSt. Jude Children's Research Hospital · USLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PL
Funding
Mechanisms of Susceptibility and Resistance of Mycobacterium tuberculosis to Isoxyl and ThiacetazoneR21AI130929 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2017 to 2018
$442kInhibitors of Mycobacterium tuberculosis FAS-II dehydratasesR21AI153477 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2020 to 2021
$376kNIAID NIH HHS R21 AI130929NIAID NIH HHS R21 AI153477
6 · The paper itselfAbstract
Phenotypic screening of inhibitors of the essential
Indexed as
Mycobacterium tuberculosisBacterial ProteinsFatty Acid Synthase, Type IIMycolic AcidsBacterial ProteinsFatty Acid Synthase, Type IIMycolic Acids(3R)-hydroxyacyl-ACP dehydratasedrug developmentFAS-IIMycobacteriummycolic acidsphenotypic screeningtuberculosisβ-ketoacyl synthase
Identifiers
PMID33139282
PMCPMC7927822
OpenAlexW3094851311
What OpenQuestion holds
Textmetadata
Read underepoch 390